http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103784435-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103784435-B |
| titleOfInvention | The application of physalin A in preparation JAK2-STAT3 signal pathway inhibitor and antitumor drug |
| abstract | The invention discloses the application of physalin A in preparation JAK2-STAT3 signal pathway inhibitor and antitumor drug, described physalin A is the compound of formula I structure; JAK2-STAT3 signal pathway inhibitor can suppress kinds of tumor cells, the non-controllability growth of the tumor caused due to JAK2-STAT3 abnormal activation, apoptosis of tumor cells resistance, further inhibition tumor cell propagation and inducing apoptosis of tumour cell.Physalin A can be applicable to prepare antitumor drug, and physalin A combines the propagation of the obvious inhibition tumor cell of energy with chemotherapeutic (cisplatin), reach the object of efficacy enhancing and toxicity reducing.Particularly physalin A and cisplatin combined use are prepared antitumor drug tablet and can produce very strong synergism, the antitumor drug tablet of preparation has extraordinary anti-tumor activity. |
| priorityDate | 2014-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 155.